stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. CATX
    stockgist
    HomeTop MoversCompaniesConcepts
    CATX logo

    Perspective Therapeutics, Inc.

    CATX
    AMEX
    Healthcare
    Medical - Devices
    Seattle, WA, US138 employeesperspectivetherapeutics.com
    $4.41
    -0.01(-0.34%)

    Mkt Cap $325M

    $1.71
    $5.65

    52-Week Range

    At a Glance

    AI-generated
    8-K
    Perspective Therapeutics, Inc. updated its corporate presentation on April 1, 2026, highlighting its 212Pb-based radiopharmaceutical pipeline including ongoing Phase 1/2a trials for VMT-α-NET, VMT01, and PSV359.

    $325M

    Market Cap

    —

    Revenue

    —

    Net Income

    Employees138
    Fundamentals

    How The Business Makes Money

    Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

    Industry Medical - Devices
    Activity

    What Changed Recently

    Material Agreement
    Feb 2, 2026

    Entry into a Material Definitive Agreement. On February 2, 2026, Perspective Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Und

    Financial Results
    Feb 1, 2026

    Results of Operations and Financial Condition. On February 2, 2026, Perspective Therapeutics, Inc. (the "Company") updated its corporate presentation (the "Pres

    Other Event
    Mar 31, 2026

    . ## Item 9.01 Financial Statements and Exhibits. (d) Exhibits | Exhibit No. | | Description | |---|---|---| | 99.1 | | Corporate Presentation . | | 104 | | Cov

    Other Event
    Jan 13, 2026

    . Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation . 104 Cover Page Interactive Data File (embedded

    Other Event
    Jan 11, 2026

    Other Events. On January 12, 2026, Perspective Therapeutics, Inc. (the "Company") issued a press release (the "Press Release") announcing certain business updat

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    AVRAnteris Technologies Glob...$5.50+3.29%$202M-1.4
    ELMDElectromed, Inc.$23.36-1.25%$195M—
    PROFProfound Medical Corp.$6.39-2.14%$193M-3.6
    IVVDInvivyd, Inc.$1.27-4.51%$169M-4.9
    TLSITriSalus Life Sciences, I...$4.22+1.08%$160M-4.7
    NNOXNano-X Imaging Ltd.$2.42+0.62%$155M-2.8
    NYXHNyxoah S.A.$3.56+12.15%$133M-1.2
    STIMNeuronetics, Inc.$1.52+2.35%$106M-2.8
    Analyst View
    Company Profile
    CIK0000728387
    ISINUS46489V3024
    CUSIP46489V302
    Phone509 375 1202
    Address350 Hills Street, Seattle, WA, 99354, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice